KDL Biotech Peer Comparison

NSE: KOPDRUGS | BSE: 532291

₹2.14

₹-0.11 (-4.89%)

As on 16-Mar-2015IST

Market cap

₹5 Cr

Revenue (TTM)

₹26 Cr

P/E Ratio

P/B Ratio

-0.1

Div. Yield

0 %

Edit

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	5	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	--	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-14.20	414.00	288.22	-371.81	387.35
Net Margin (%)	-6,396.85	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	-0.05	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	26.47	4,350.50	34.80	--	33.90
Total Income	27.22	4,375.84	34.80	--	34.61
Total Expenditure	28.53	2,996.79	25.65	--	30.42
EBITDA	-2.07	1,353.71	9.15	--	3.48
Depreciation	9.13	115.07	2.71	--	1.05
EBIT	-11.20	1,238.64	6.44	--	2.42
Interest	6.77	269.02	2.51	--	1.10
Other Income	0.76	25.34	0.42	--	0.71
Exceptional Items	-11.50	-473.77	--	--	--
Profit before Tax	-17.21	521.19	3.93	--	2.03
Provision for Tax	7.69	221.74	1.40	--	0.68
Profit after Tax	-17.21	299.45	2.52	--	1.35

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	-59.17	1,471.02	37.49	--	6.11
Minority Interest	--	--	--	--	--
Non-Current Liabilities	2.66	2,891.88	5.39	--	0.04
Current Liabilities	113.21	1,890.94	24.92	--	15.82
Total Liabilities	56.70	6,253.84	67.79	--	22.09

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	49.80	3,772.33	47.64	--	5.51
Current Assets	6.89	2,481.51	20.15	--	16.45
Total Assets	56.70	6,253.84	67.79	--	22.09
Total Debt*	60.26	3,492.50	19.14	--	6.41
Net Current Assets	-106.32	590.57	-4.76	--	0.63
Contingent Liabilities	90.96	46.91	0.71	--	--

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	6.79	1,343.83	5.07	--	--
Cash Flow from Investing Activities	0.00	-305.45	-4.60	--	--
Cash from Financing Activities	-6.73	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	0.06	211.82	-0.36	--	0.00

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-108.39	16.20	12.09	--	25.61
ROE (%)	0.00	66.74	14.65	--	24.87
ROA (%)	-28.21	4.97	4.06	--	6.42
EBIT Margin (%)	-4.94	31.70	26.29	--	12.34
Net Margin (%)	-63.22	6.84	7.25	--	3.90
Cash Profit Margin (%)	-29.64	9.52	15.04	--	6.56

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-6.83	15.97	65.29	--	21.86
EBIT Growth (%)	91.84	29.05	42.04	--	27.63
Net Profit Growth (%)	73.24	212.90	6.25	--	7.55
EPS Growth (%)	73.24	278.36	6.25	--	7.55
Book Value Growth (%)	-41.02	253.45	15.81	--	28.51

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	17.64	0.00	--	0.00
Price / Book Value	-0.15	9.37	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-52.39	7.33	4.36	--	1.71
Market Cap (₹ Cr)	8.80	6,555.46	0.00	--	0.00

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-1.02	2.39	0.51	--	1.05
Short term debt to equity ratio	-0.87	0.18	0.21	--	0.88
Current Ratio	0.06	1.31	0.81	--	1.04
Quick Ratio	0.04	0.84	0.77	--	0.66
Interest Coverage	-1.54	2.94	2.57	--	2.86

	KDL Biotech	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	0.06	17.44	42.51	--	24.27
Asset Turnover	0.45	0.72	0.56	--	1.74
Receivable days	2.08	57.17	120.33	--	81.45
Inventory Days	34.92	67.16	9.04	--	45.36
Payable days	425.93	116.25	535.25	--	134.63
Cash Conversion Cycle	-388.93	8.07	-393.94	--	-7.82

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.